Valuation: Nippon Shinyaku Co., Ltd.

Capitalization 366B 2.35B 1.99B 1.83B 1.72B 3.22B 215B 3.41B 20.85B 8.34B 102B 8.82B 8.63B P/E ratio 2026 *
13.4x
P/E ratio 2027 * 14x
Enterprise value 296B 1.9B 1.61B 1.48B 1.39B 2.6B 174B 2.75B 16.85B 6.74B 82.37B 7.12B 6.97B EV / Sales 2026 *
1.76x
EV / Sales 2027 * 1.51x
Free-Float
90.75%
Yield 2026 *
2.3%
Yield 2027 * 2.32%
More valuation ratios * Estimated data
Dynamic Chart
12-22 Nippon Shinyaku Co says Johnson & Johnson obtains approval of Opsumit RE
12-17 Jefferies Adjusts Nippon Shinyaku's Price Target to 6,200 Yen from 3,000 Yen, Keeps at Hold MT
12-16 Capricor Therapeutics Announces Positive Topline Results From Phase 3 HOPE-3 Trial Of Deramiocel For Duchenne Muscular Dystrophy CI
12-05 JPMorgan Upgrades Nippon Shinyaku to Overweight from Neutral; Price Target is 8,000 Yen MT
11-13 Nippon Shinyaku Co., Ltd. Announces Second Quarter End Dividend for the Six Months Ended September 30, 2025, Payable on December 5, 2025 CI
11-13 Nippon Shinyaku Co., Ltd. Provides Earnings Guidance for the Full Year Ending March 31, 2026 CI
25-09-24 Jefferies Adjusts Nippon Shinyaku's Price Target to 3,000 Yen From 2,900 Yen, Keeps at Hold MT
25-09-19 Fda grants orphan drug designation to Ns-051/Ncnp-04 for treatment of Duchenne muscular dystrophy RE
25-07-14 Jefferies Adjusts Nippon Shinyaku's Price Target to 2,900 Yen From 3,500 Yen, Keeps at Hold MT
25-05-13 REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II CI
25-05-09 Jefferies Adjusts Nippon Shinyaku's Price Target to 3,500 Yen From 3,800 Yen, Keeps at Hold MT
25-05-07 Nippon Shinyaku Co., Ltd. Provides Earnings Guidance for the Fiscal First Half of 2026 and Full Year Ending March 31, 2026 CI
25-05-07 Nippon Shinyaku Co., Ltd. Announces Dividend for the Fiscal Full Year Ended March 31, 2025, Payable on June 30, 2025; Provides Dividend Guidance for the Fiscal First Half of 2026 and Full Year Ending March 31, 2026 CI
More news
1 day-0.80%
1 week-3.23%
Current month-3.88%
1 month-7.59%
3 months+61.21%
6 months+78.89%
Current year-3.88%
More quotes
1 week 5,320
Extreme 5320
5,480
1 month 5,320
Extreme 5320
5,855
Current year 5,320
Extreme 5320
5,787
1 year 2,967
Extreme 2967
6,529
3 years 2,694
Extreme 2694
6,790
5 years 2,694
Extreme 2694
9,840
10 years 2,694
Extreme 2694
10,360
More quotes
Manager TitleAgeSince
Director of Finance/CFO - -
President 54 2021-05-31
Chief Administrative Officer 65 2018-05-31
Director TitleAgeSince
Chairman 73 2021-05-31
Director/Board Member 68 2023-05-31
Director/Board Member 65 2015-05-31
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-0.80%-3.23%+44.33%-18.82% 2.33B
-2.12%+3.03%+41.16%+207.54% 974B
+0.76%+0.26%+51.54%+30.46% 526B
+0.53%+1.16%+29.59%+46.57% 385B
+0.06%+0.69%+27.14%+18.28% 376B
+0.15%-3.18%+23.01%+21.25% 284B
+0.47%+1.01%+28.88%+36.88% 279B
+1.17%+9.90%-30.99%-16.90% 277B
-0.92%-2.51%+13.06%-1.60% 271B
-0.67%+4.46%+26.08%+30.96% 187B
Average -0.01%+1.30%+25.38%+35.46% 356.19B
Weighted average by Cap. +0.09%+2.10%+29.01%+72.96%
See all sector performances

Financials

2026 *2027 *
Net sales 168B 1.08B 913M 842M 792M 1.48B 98.95B 1.57B 9.58B 3.83B 46.85B 4.05B 3.97B 188B 1.21B 1.02B 943M 888M 1.66B 111B 1.75B 10.73B 4.29B 52.48B 4.54B 4.44B
Net income 27.21B 175M 148M 136M 128M 239M 16.01B 253M 1.55B 620M 7.58B 655M 642M 26.06B 167M 141M 130M 123M 229M 15.33B 243M 1.48B 594M 7.26B 628M 615M
Net Debt -70.34B -452M -382M -352M -331M -618M -41.38B -655M -4.01B -1.6B -19.59B -1.69B -1.66B -81.6B -524M -443M -408M -384M -718M -48.01B -760M -4.65B -1.86B -22.73B -1.97B -1.92B
More financial data * Estimated data
Logo Nippon Shinyaku Co., Ltd.
Nippon Shinyaku Co., Ltd. is a Japan-based company principally involved in the manufacture and sale of pharmaceutical products and functional foodstuffs. The Company operates in two business segments. The Pharmaceutical segment is involved in the manufacture and sale of urinary system therapeutic agents, blood cancer therapeutic agents, pain, inflammation and allergic therapeutic agents, digestive system therapeutic agents, cardiovascular systems and metabolic therapeutic agents. The Functional Foodstuff segment involves in the manufacture and sale of health food materials, quality stability preservatives, protein preparation, spice and seasoning products. The Company is also involved in the business support business, non-life insurance agency business, as well as the provision of real estate leasing services.
Employees
2,243
More about the company
Date Price Change Volume
26-01-23 5,431.00 ¥ -0.80% 364,700
26-01-22 5,475.00 ¥ +1.35% 279,800
26-01-21 5,402.00 ¥ +0.41% 472,700
26-01-20 5,380.00 ¥ -0.19% 256,300
26-01-19 5,390.00 ¥ -0.13% 392,300

Delayed Quote Japan Exchange, January 23, 2026 at 01:30 am

More quotes
Trader
Investor
Global
Quality
ESG MSCI
A
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
5,431.00JPY
Average target price
6,200.00JPY
Spread / Average Target
+14.16%
Consensus

Quarterly revenue - Rate of surprise